Effect of radiotherapy on the survival of cervical cancer patients

Yang, Jian; Cai, Haoyang; Xiao, Zhi; Wang, Hangyu; Yang, Ping

doi:10.1097/md.0000000000016421

Cited by 56 publications

(51 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FIGO stage was classified by the 2009 FIGO stage system. And the continuous predictors (age and tumor size) were divided into subgroups by previously reported cutoff points [6,16]. The time calculated from diagnosis to dead or censored was defined as overall survival.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study

et al. 2020

View full text Add to dashboard Cite

Background: Cervical cancer has long been a common malignance troubling women. However, there are few studies developing nomogram with comprehensive factors for the prognosis of cervical cancer. Hence, we aimed to build a nomogram to calculate the overall survival (OS) probability in patients with cervical cancer. Methods: Data of 9876 female patients in SEER database and diagnosed as cervical cancer during 2010-2015, was retrospectively analyzed. Univariate and multivariate Cox proportional hazard regression model were applied to select predicted factors and a nomogram was developed to visualize the prediction model. The nomogram was compared with the FIGO stage prediction model. Harrell's C-index, receiver operating curve, calibration plot and decision curve analysis were used to assess the discrimination, accuracy, calibration and clinical utility of the prediction models. Result: Eleven independent prognostic variables, including age at diagnosis, race, marital status at diagnosis, grade, histology, tumor size, FIGO stage, primary site surgery, regional lymph node surgery, radiotherapy and chemotherapy, were used to build the nomogram. The C-index of the nomogram was 0.826 (95% CI: 0.818 to 0.834), which was better than that of the FIGO stage prediction model (C-index: 0.785, 95% CI: 0.776 to 0.793). Calibration plot of the nomogram was well fitted in 3-year overall OS prediction, but overfitting in 5-year OS prediction. The net benefit of the nomogram was higher than the FIGO prediction model. Conclusion: A clinical useful nomogram for calculating the overall survival probability in cervical cancer patients was developed. It performed better than the FIGO stage prediction model and could help clinicians to choose optimal treatments and precisely predict prognosis in clinical care and research.

show abstract

Section: Patientsmentioning

confidence: 99%

“…Therefore, using FIGO stage system to estimate prognosis of cervical cancer is not entirely satisfactory. And many other factors have been identified related to the survival of cervical cancer [5,6].…”

Section: Introductionmentioning

confidence: 99%

Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus, an increased external pelvic dose will probably not compensate for exclusion of brachytherapy treatment. Prior studies have also confirmed the advantage of combined external and intracavitary therapy compared with external therapy alone [8,16,17]. The total dose (D90) to the HRCTV (external plus intracavitary) was significantly higher in the group treated with needles.…”

Section: Vaginal Toxicity (Only Recorded In the Igabt-group)mentioning

confidence: 80%

A comparison of external pelvic chemoradiation and high dose-rate conventional brachytherapy (BT) and image-guided adaptive brachytherapy (IGABT) in treatment of advanced cervical carcinomas

2020

ARCH Women Health Care

View full text Add to dashboard Cite

“…Thus, an increased external pelvic dose (or boost dose) would probably not compensate for exclusion of brachytherapy treatment. Prior studies have also confirmed the advantage of combined external and intracavitary therapy compared with external therapy alone [9,14]. On the other hand, the size of HRCTV and the use of interstitial needles were neither statistically associated with tumor recurrences nor with cancer-specific survival rate in the complete series.…”

Section: Discussionmentioning

confidence: 95%

Combined external pelvic chemoradiotherapy and image-guided adaptive brachytherapy in treatment of advanced cervical carcinoma: experience from a single institution

Möller

Mordhorst

Hermansson

et al. 2020

jcb

View full text Add to dashboard Cite

Purpose: External pelvic chemoradiotherapy and image-guided adaptive brachytherapy (IGABT) were studied in advanced cervical carcinomas. Treatment modalities were defined and related to outcomes and side effects. Material and methods: From a single cancer center, 138 patients with advanced cervical cancer were recruited. All patients were treated with external radiotherapy and IGABT. A dosimetric study was performed and related to treatment outcome and side effects. Toxicity of the organs at risk was evaluated by the CTCAE-grading system. Results: The median follow-up was 44 months. More than 60% of the tumors were FIGO stage IIB-IIIB and 82% were squamous cell carcinomas. Largest tumor size (width) was in mean 41 mm and 27% had lymph node spread. The mean total external dose was 51 Gy, and the mean total dose to the high-risk clinical target volume (HRCTV) was 88 Gy. In 130 patients (94%), weekly cisplatin was given in 4-6 cycles. The median number of brachytherapy fractions was four, and in 86 patients, interstitial needles were applied. The primary local control was 97% and 94% after four local recurrences. The overall pelvic control was 89%. The overall recurrence rate was 25% and distant metastases rate was 22%. The overall 5-year survival rate was 65% and cancer-specific survival rate was 69%. Prognostic factors were FIGO stage and total brachytherapy dose (D 90) to HRCTV. Late serious toxicity of the bladder and intestine were rare, occurring in only 3% of patients. Conclusions: The local and pelvic control rates were excellent in this series. The IGABT was an important part of the treatment schedule and could probably not be replaced by increasing the external pelvic dose. Adenocarcinomas seemed to benefit from the addition of interstitial needles. Late serious toxicity was rare.

show abstract

Effect of radiotherapy on the survival of cervical cancer patients

Abstract: Supplemental Digital Content is available in the text

Cited by 56 publications

References 33 publications

Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study

Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study

A comparison of external pelvic chemoradiation and high dose-rate conventional brachytherapy (BT) and image-guided adaptive brachytherapy (IGABT) in treatment of advanced cervical carcinomas

Combined external pelvic chemoradiotherapy and image-guided adaptive brachytherapy in treatment of advanced cervical carcinoma: experience from a single institution

Contact Info

Product

Resources

About